Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics

Open Access

Peer-reviewed

Research Article

Gary Mo,

Affiliations Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States of America, DMPK Modeling and Simulation, Oncology, iMED, AstraZeneca, Waltham, Massachusetts, United States of America
⨯
Frank Gibbons,

Affiliation DMPK Modeling and Simulation, Oncology, iMED, AstraZeneca, Waltham, Massachusetts, United States of America
⨯
Patricia Schroeder,

Affiliation DMPK Modeling and Simulation, Oncology, iMED, AstraZeneca, Waltham, Massachusetts, United States of America
⨯
Wojciech Krzyzanski

* E-mail: wk@buffalo.edu

Affiliation Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States of America
⨯

Reader Comments (0)

Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cell cycle and cell division
Is the Subject Area "Cell cycle and cell division" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.
Cell division analysis
Is the Subject Area "Cell division analysis" applicable to this article?

Thanks for your feedback.
Pharmacokinetics
Is the Subject Area "Pharmacokinetics" applicable to this article?

Thanks for your feedback.